Cited by

• Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.

  Cadman E, Eiferman F. Cadman E, et al. J Clin Invest. 1979 Sep;64(3):788-97. doi: 10.1172/JCI109525. J Clin Invest. 1979. PMID: 288743 Free PMC article.
• Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.

  Carson DA, Wasson DB, Kaye J, Ullman B, Martin DW Jr, Robins RK, Montgomery JA. Carson DA, et al. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6865-9. doi: 10.1073/pnas.77.11.6865. Proc Natl Acad Sci U S A. 1980. PMID: 6256765 Free PMC article.
• Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.

  Reichelová V, Juliusson G, Spasokoukotskaja T, Eriksson S, Liliemark J. Reichelová V, et al. Cancer Chemother Pharmacol. 1995;36(6):524-9. doi: 10.1007/BF00685803. Cancer Chemother Pharmacol. 1995. PMID: 7554045
• Antineoplastic and immunosuppressive drugs. I. Biochemical and clinical pharmacological considerations.

  Chalmers AH, Burgoyne LA, Murray AW. Chalmers AH, et al. Drugs. 1972;3(3):227-53. doi: 10.2165/00003495-197203030-00004. Drugs. 1972. PMID: 4561638 Review. No abstract available.
• An Escherichia coli system expressing human deoxyribonucleoside salvage enzymes for evaluation of potential antiproliferative nucleoside analogs.

  Wang J, Neuhard J, Eriksson S. Wang J, et al. Antimicrob Agents Chemother. 1998 Oct;42(10):2620-5. doi: 10.1128/AAC.42.10.2620. Antimicrob Agents Chemother. 1998. PMID: 9756765 Free PMC article.